Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke

Ana I. Casas, …, Christoph Kleinschnitz, Harald H.H.W. Schmidt


Graphical abstract

Find the latest version:

http://jci.me/124283/pdf
Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke

Ana I. Casas, Pamela W.M. Kleikers, Eva Geuss, Friederike Langhäuser, Thure Adler, Dirk H. Busch, Valerie Gailus-Durner, Martin Hrabê de Angelis, Javier Egea, Manuela G. Lopez, Christoph Kleinschnitz, and Harald H.H.W. Schmidt

Ischemic stroke is a predominant cause of disability worldwide, with thrombolytic or mechanical removal of the occlusion being the only therapeutic option. Reperfusion bears the risk of an acute deleterious calcium-dependent breakdown of the blood-brain barrier. Its mechanism, however, is unknown. Here, we identified type 5 NADPH oxidase (NOX5), a calcium-activated, ROS-forming enzyme, as the missing link. Using a humanized knockin (KI) mouse model and in vitro organotypic cultures, we found that reoxygenation or calcium overload increased brain ROS levels in a NOX5-dependent manner. In vivo, posts ischemic ROS formation, infarct volume, and functional outcomes were worsened in NOX5-KI mice. Of clinical and therapeutic relevance, in a human blood-barrier model, pharmacological NOX inhibition also prevented acute reoxygenation-induced leakage. Our data support further evaluation of poststroke recanalization in the presence of NOX inhibition for limiting stroke-induced damage.

Introduction

Ischemic stroke represents one of the most frequent causes of death and leading causes of disability worldwide (1). Thrombolytic or mechanical removal of the occlusion is the only therapeutic option (2). In 11% of the mechanically recanalized patients, however, serious complications occur (3), and thrombolysis using tissue plasminogen activator (rtPA) correlates with an early opening of the blood-brain barrier (BBB), edema, and hemorrhagic transformation, with excessive ROS production and worse prognosis (4). Importantly, an increase in intracellular calcium represents one of the earliest events during this scenario (2, 5). Pharmacological agents that selectively inhibit the activity of ROS-forming enzymes, i.e., NADPH oxidase, are active in poststroke models (6). Antioxidants have been used to restore redox imbalances and improve disease outcomes, although with mostly ineffective results (6, 7). We therefore implemented an innovative approach that uses pharmacological agents that selectively inhibit the activity of ROS-forming enzymes (8).

NADPH oxidases are considered a primary and quantitatively relevant source in different ischemic conditions (5). Of particular interest is NADPH oxidase type 5 (NOX5), the only calcium-activated isoform widely expressed in endothelium (7), testis, and WBCs (8). We hypothesized that NOX5 may be the missing link between postreperfusion calcium overload and early BBB opening. Since NOX5 is missing from the mouse genome, we generated a humanized mouse model expressing the human NOX5 gene. To validate its role in acute recanalization, we examined both a pharmacological approach in a human in vitro BBB model and a genetic approach in an in vivo stroke model in mice.

Results and Discussion

Generation and validation of a humanized NOX5-KI mouse model. In humans, NOX5 is broadly expressed in vascular endothelium, fibroblasts (7, 9, 10), testis (9), and spleen monocytes, macrophages (8), B cells, and T cells (12). To mimic the physiological human expression pattern of NOX5 in mice, we created a mouse line called NOX5-knockin (NOX5-KI), bearing the human NOX5 gene under control of the Tie2 promoter (Figure 1, A and B). The Tie2 promoter physiologically regulates endothelial and hematopoietic gene expression in human cells (13, 14). Therefore, we expected our transgenic mouse model to mimic physiological human NOX5 expression.

Tissues from WT mice did not show any detectable NOX5 gene expression, while significant expression was detected in all KI mice (Figure 1C), primarily in lung, kidney, brain, aorta, and WBCs (monocytes, lymphocytes, T and B cells; Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI124283DS1). Thus, our Tie2-NOX5-KI mouse model is ideally humanized with respect to the...
In vitro, NOX5 causes acute, calcium-dependent postreoxygenation ROS formation. With respect to ischemic stroke, delayed induction of NOX4 was identified as a relevant source of ROS (5, 17), but neither NOX1 nor NOX2 was identified as such (18), and the role of NOX5 is unclear. To examine whether NOX5 is relevant for ROS formation upon cerebral reoxygenation, we first studied in vitro organotypic hippocampal cultures (OHCs) from NOX5-KI and WT mice. To detect ROS species as broadly as possible, including secondary reactions and not differentiating among superoxide, hydrogen peroxide, hydroxyl, or possibly peroxynitrite, we chose the dihydroethidium (DHE) method, as published previously (17, 19). Fifteen minutes of oxygen and glucose deprivation (OGD) (Figure 2A) resulted, unlike with NOX4, in an acute NOX5-
dependent ROS production within the first 30 minutes that was not present in WT mice (Figure 2, B and C). At later time points, ROS formation was unchanged, presumably due to the known, delayed induction of NOX4 (20). To confirm that the early spike in ROS was indeed due to calcium-induced activation of NOX5, we reexamined ROS generation in OHCs from NOX5-KI and WT mice in the absence or presence of the calcium ionophore A23187 (10 μM), but without OGD. Indeed, we observed the same acute ROS surge as seen after OGD and in a strictly NOX5-dependent manner (Figure 2, D and E). Thus, NOX5-dependent ROS formation is involved in early stages after ischemia via a Ca\textsuperscript{2+}-dependent mechanism.

In vivo, ROS formation and BBB breakdown are NOX5 dependent and worsen neurological outcome. To examine the role of NOX5 in a stroke in vivo, we performed a 1-hour transient occlusion of the middle cerebral artery (tMCAO) on adult mice, followed by 24 hours of reperfusion (Figure 3A) for histological and neurological assessment. Reperfusion injury leads to an abnormally permeable capillary bed, resulting in a disruption of the BBB (4). BBB leakage was significantly increased in brains from NOX5-KI mice when compared with their WT littermates, indicating also here a key role for NOX5 in poststroke BBB integrity (Figure 3B). To examine the mechanistic link between this observation and NOX5 activity, we measured ROS formation in NOX5-KI and WT mice. Again, ROS generation was significantly increased in poststroke NOX5-KI mice compared with controls (Figure 3C). Thus, poststroke NOX5-dependent impairment of the BBB is related to enhanced in vivo ROS formation.

To further evaluate, 24 hours after stroke, whether NOX5-dependent ROS formation and impairment of the BBB were linked to a worsened outcome, we assessed infarct sizes and, as a clinical translational parameter, neuromotor function. Importantly, poststroke NOX5-KI mice, when compared with WT mice, showed a significant increase in infarct volume (Figure 3D) and worsened Bederson score and grip tests (Figure 3, E and F; see Supplemental Methods). Thus, acute postreoxygenation Ca\textsuperscript{2+}-dependent ROS formation, BBB breakdown, increased infarct size, and worsened neuromotor outcome are mechanistically linked to NOX5.

Blood pressure does not contribute as a confounder to the NOX5-KI phenotype in stroke. Conceivably, an endothelial NOX5-KI may lead to a systemic constitutively elevated endothelial ROS formation linked to increased blood pressure. Hypertension can weaken brain arteries and indirectly worsen stroke outcome (21), which may result in possible overestimation of direct NOX5 impact. We therefore also assessed blood pressure over 24 hours using telemetric devices. Neither systolic, diastolic, nor mean arterial pressure (Supplemental Figure 2, A–C) were different between WT and NOX5-KI mice, suggesting that no systemic hypertensive phenotype confounded the worsened postreperfusion in vivo outcome in NOX5-KI mice.

The role for NOX5-KI in ischemia reperfusion is specific to the brain. In principle, knocking in NOX5 in the vascular endothelium may worsen outcomes in many ischemia-reperfusion (IR) scenarios in different organs and thus play no brain-specific role. Indeed, for NOX1 and NOX2, such roles have been described in myocardial infarction (MI) (22), retinopathy (23), or diabetic nephropathy (24, 25). Moreover, NOX5 is upregulated in human blood vessels after MI (26). We therefore investigated in vivo 3 different relevant ischemic-disease conditions: hindlimb ischemia (HL, peripheral artery disease), MI, and IR of the heart.
To test the translatability of our findings into the clinical setting, i.e., pharmacological intervention, we used a primary culture of human brain microvascular endothelial cells (HBMECs) as an in vitro ischemia model (Figure 4A). Importantly, thrombectomy procedures have been recently associated with reperfusion damage and early BBB disruption, hemorrhagic transformation, and poor clinical outcomes. Thus, clinical trials have been designed to pharmacologically block the BBB opening in patients undergoing poststroke recanalization (4). Here, calcium is critical for tight junction function, particularly for cerebral microvessels and BBB stability, and poststroke calcium overload is a key mechanism of BBB disruption. Thus, we hypothesized that NOX5 is the missing mechanistic link in early BBB disruption and reperfusion injury.

We subjected HBMECs expressing NOX5 endogenously to 6 hours of hypoxia, followed by 24 hours of reoxygenation and assessment of cell permeability (Figure 4B) in the presence or absence of the relatively NOX5-specific inhibitor ML090 (0.01 μM; Supplemental Figure 4). Importantly, delayed induction of NOX4 also contributes to BBB disruption (17) and needed to be taken into consideration (Supplemental Figure 5). Hence, HBMECs were also treated both acutely and after reoxygenation with the relatively NOX4-specific inhibitor M13 (0.2 μM) (Figure 4C). While the NOX4 inhibitor was protective when added either early or late, the NOX5 inhibitor was only protective when added early (Figure 4D). To finally test the possibility of a role for calcium-dependent...
PKC and direct NOX2 activation (28), HBMECs were also treated before reoxygenation with the PKC inhibitor GF109203X (0.3 μM), which, however, showed no effect, suggesting no relevant role of NOX2 (Supplemental Figure 6), in agreement with a previous in vivo preclinical randomized confirmatory trial (18). Thus, the role of calcium in acute BBB breakdown after reoxygenation/reperfusion in stroke can be fully explained by NOX5, while NOX4 induction plays a key role in later stages. The efficacy of ML090 suggests a preventive pharmacotherapeutic option, ideally as a pretreatment or through coadministration with a thrombolytic drug, i.e., rtPA or a thrombectomy procedure.

Thus, we here identify NOX5-derived ROS as a missing link in acute stroke therapy between postreperfusion calcium surge, BBB breakdown, and worsened outcome. NADPH oxidases in general are promising therapeutic targets in ROS-associated diseases (5, 6, 29). Since most preclinical validation experiments are conducted in mice and rats, which lack the NOX5 gene, NOX5 has been understudied. We provide what we believe is the first humanized NOX5-KI mouse model that mimics, to a large extent, the physiological pattern of NOX5 expression in humans, with substantial expression in endothelial cells and WBCs. In principle, our observed in vivo phenotype in NOX5-KI mice could thus derive from endothelial cells and WBCs, and we certainly cannot completely rule out a contribution of the latter. However, several lines of evidence support a fully sufficient role of endothelial NOX5. First, our in vitro mouse organotypic culture, essentially free of WBC contributions, and second, our HBMEC model, per definition entirely free of WBCs, are in full agreement with a crucial endothelial location of NOX5. Third, the detrimental role of NOX5 after reperfusion was highly specific for brain; NOX5 played no acute role in MI, transient heart ischemia, or HL, suggesting indirectly the BBB and its cellular components as the main location of NOX5. Moreover, endothelial NOX5 would already be at the site of action with respect to BBB breakdown, whereas WBCs would need to adhere, and only a fraction of them would be preexposed to postreperfusion cal-

Figure 4. NOX5 inhibition before reoxygenation reduced cell permeability to basal levels using a human in vitro ischemia model. (A) HBMECs were seeded on Transwell inserts, where cell permeability was assessed using Evans blue dye. (B) After incubation and seeding under normoxic conditions, HBMECs were subjected to 6 hours of hypoxia and 24 hours of reoxygenation. Cells were treated with both NOX4 (M13) and NOX5 inhibitors (ML090) at early (20 minutes before reoxygenation) and late (20 minutes after reoxygenation) time points. (C) Cell permeability was assessed by measuring Evans blue fluorescence after hypoxia. Evans blue diffusion was significantly reduced in cells subjected to early treatment of ML090 (0.01 μM), which preferably inhibits NOX5, and M13 (0.2 μM), which is mainly a NOX4 inhibitor (*P < 0.05, 2-tailed unpaired t test). In contrast, late treatment was only effective after M13 (0.2 μM) treatment compared with that of nontreated cells (***P < 0.01). Reox, reoxygenation. (D) NOX5 activation takes place within the first 30 minutes to 1 hour after hypoxia (see Figure 3), while NOX4 activation peak appears at around 5 hours after ischemia (20). Data are represented as mean ± SEM in all experiments. NOX4i, NOX4 inhibitor.
cium surges. We also cannot exclude the possibility that NOX5 in other nonendothelial or non-WBC types may also contribute in vivo. From a clinical translational point of view, this may be a minor limitation because NOX5-directed pharmacotherapies, e.g., small molecules such as ML090, will always act systemically and not in a cell-specific manner.

Therapeutically, one additional aspect is worth considering, i.e., the previous identification of neuronal (and endothelial) NOX4 in stroke (17, 19). This enzyme does not contribute to the here-investigated early stages of BBB opening. Therefore, any prospective therapy will ideally want to cover both isoforms, acutely induced NOX5 and subacutely (i.e., within 4 to 6 hours) induced NOX4, to further inhibit the detrimental role of NOX4 and NOX5 at different stages of the pathomechanism.

Of direct clinical importance, our data suggest that thrombolysis and thrombectomy should be conducted in the presence of NOX inhibition to minimize the chances of a postreperfusion, calcium- and ROS-dependent acute and deleterious opening of the BBB. Our findings provide a clear rationale for further development of a pharmacological NOX4/5 inhibitor as a first-in-class neuroprotective strategy after stroke, to be coadministered with the onset of reperfusion.

Methods
Details are provided in the Supplemental Methods.

Statistics. All data are expressed as mean ± SEM. Statistical differences between mean continuous values were determined by Student’s 2-tailed t test. For repeated measurements, 2-way ANOVA was used.

Study approval. All animal experiments were performed according to the EU Directive 2010/63/EU for animal experiments, the German Animal Welfare Act, and Dutch law on animal experiments (Centrale Commissie Dierproeven). Experiments were approved by the responsible authority of the Regierung von Oberbayern (Germany) and the Institutional Ethics Committee of the Universidad Autónoma de Madrid.

Author contributions
AIC, PWMK, and EG performed in vivo and in vitro experiments and data analysis and contributed to writing the manuscript. TA performed immunological phenotyping, which DHB, VGD, and MHDA supervised. JE helped with data acquisition, and FL helped with sample collection. HHWS designed experiments, contributed to writing the manuscript, and acquired funding. MGL, CK, and JE acquired funding and methods. JE helped with some in vitro experiments and animal breeding.

Acknowledgments
This work was supported by the European Research Council, AdG RadMed 294683, an ERC PoC grant, SAVEBRAIN 139-101052, and H2020 project REPO-TRIAL (to HHWS), the Spanish Ministry of Economy and Competence (SAF2015-63935R to MGL), the Deutsche Forschungsgemeinschaft (to CK), the Fondo de Investigaciones Sanitarias (CP14/00008 and PI16/00735 to JE), European Cooperation in Science and Technology and Kootstra fellowships (to AIC), and the Bundesministerium für Bildung und Forschung (to MHDA). A. Bruins-Strzelecka, J. Debets, and H. van Essen are gratefully acknowledged for their expert technical support. We thank K. Wingler for help with generating and breeding of NOX5KI mice.

Address correspondence to: Harald H.H. Schmidt, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands. Phone: 31.43.3881421; Email: h.schmidt@maastrichtuniversity.nl.

3. Behme D, Gondecki L, Fiethen S, Kowoll A, AIC, PWMK, and EG performed in vivo and in vitro experiments and data analysis and contributed to writing the manuscript. TA performed immunological phenotyping, which DHB, VGD, and MHDA supervised. JE helped with data acquisition, and FL helped with sample collection. HHWS designed experiments, contributed to writing the manuscript, and acquired funding. MGL, CK, and JE acquired funding and methods. JE helped with some in vitro experiments and animal breeding.

Acknowledgments
This work was supported by the European Research Council, AdG RadMed 294683, an ERC PoC grant, SAVEBRAIN 139-101052, and H2020 project REPO-TRIAL (to HHWS), the Spanish Ministry of Economy and Competence (SAF2015-63935R to MGL), the Deutsche Forschungsgemeinschaft (to CK), the Fondo de Investigaciones Sanitarias (CP14/00008 and PI16/00735 to JE), European Cooperation in Science and Technology and Kootstra fellowships (to AIC), and the Bundesministerium für Bildung und Forschung (to MHDA). A. Bruins-Strzelecka, J. Debets, and H. van Essen are gratefully acknowledged for their expert technical support. We thank K. Wingler for help with generating and breeding of NOX5KI mice.

Address correspondence to: Harald H.H. Schmidt, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands. Phone: 31.43.3881421; Email: h.schmidt@maastrichtuniversity.nl.

3. Behme D, Gondecki L, Fiethen S, Kowoll A, AIC, PWMK, and EG performed in vivo and in vitro experiments and data analysis and contributed to writing the manuscript. TA performed immunological phenotyping, which DHB, VGD, and MHDA supervised. JE helped with data acquisition, and FL helped with sample collection. HHWS designed experiments, contributed to writing the manuscript, and acquired funding. MGL, CK, and JE acquired funding and methods. JE helped with some in vitro experiments and animal breeding.

Acknowledgments
This work was supported by the European Research Council, AdG RadMed 294683, an ERC PoC grant, SAVEBRAIN 139-101052, and H2020 project REPO-TRIAL (to HHWS), the Spanish Ministry of Economy and Competence (SAF2015-63935R to MGL), the Deutsche Forschungsgemeinschaft (to CK), the Fondo de Investigaciones Sanitarias (CP14/00008 and PI16/00735 to JE), European Cooperation in Science and Technology and Kootstra fellowships (to AIC), and the Bundesministerium für Bildung und Forschung (to MHDA). A. Bruins-Strzelecka, J. Debets, and H. van Essen are gratefully acknowledged for their expert technical support. We thank K. Wingler for help with generating and breeding of NOX5KI mice.